{"database": "lobbying", "table": "lobbying_activities", "rows": [[1413039, "d17ef4c1-f56f-4466-a326-779369b71083", "Q2", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2013, "second_quarter", "PHA", "Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.H.R. 933  - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries.\n\nH.R. 2186 - VALID Compounding Act - Focused on increasing safety for compounded drugs\n\nS. 959 - Pharmaceutical Compounding Quality and Accountability Act - Focused on compounding and continued work on issues related to downstream supply chain safety of prescription medications\n\nContinued work on issues related to downstream supply chain safety of prescription medications", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2013-07-18T14:02:41.137000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1413039"], "units": {}, "query_ms": 6.1791479820385575, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}